Arrowhead Pharmaceuticals (ARWR) Other Accumulated Expenses (2012 - 2026)

Arrowhead Pharmaceuticals' Other Accumulated Expenses history runs 14 years deep, the most recent figure standing at $11.2 million for Q1 2026.

• Quarterly Other Accumulated Expenses rose 2401.12% year-over-year to $11.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.2 million (up 2401.12% YoY) and the FY2025 annual result came in at $10.8 million, up 2402.55% from the prior year.
• Other Accumulated Expenses was $11.2 million for Q1 2026 at Arrowhead Pharmaceuticals, up from $10.7 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $11.2 million in Q1 2026 and bottomed at $417000.0 in Q2 2024.
• A 4-year average of $3.9 million and a median of $461000.0 in 2023 frame the typical range for Other Accumulated Expenses.
• Peak annual rise in Other Accumulated Expenses reached 2402.55% in 2025, while the deepest fall reached 21.82% in 2025.
• Arrowhead Pharmaceuticals' Other Accumulated Expenses stood at $461000.0 in 2023, then slipped by 4.56% to $440000.0 in 2024, then soared by 2326.14% to $10.7 million in 2025, then grew by 4.96% to $11.2 million in 2026.
• Business Quant data shows ARWR's Other Accumulated Expenses at $11.2 million in Q1 2026, $10.7 million in Q4 2025, and $10.8 million in Q3 2025.